Key facts
- VerImmune’s last known valuation is $30.0M (Jul 2025).
- It has raised $10.0M across 2 recorded rounds; the latest was Seed Round ($4.5M) in Aug 2024.
- Notable investors include US National Science Foundation, Mana Ventures, Gaingels, TEDCO, Ulu Ventures — 12 tracked in total.
- VerImmune has filed 2 Form Ds with the SEC since 2022, most recently Sep 2024 ($4.5M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for VerImmune
Funding rounds
2 roundsAbout VerImmune
Developer of a virus-inspired therapeutic delivery platform designed to leverage the natural geometric structure of viruses for targeted payload transport. The company offers a self-assembling Virus-inspired Particle system that carries diverse therapeutic payloads for oncology, autoimmunity, and animal health applications, enabling researchers and developers to pursue targeted treatment strategies across multiple disease areas.
- Sector
- Healthcare
- HQ
- Germantown, MD, United States
- Founded
- 2019
- Employees
- 8
- Website
- verimmune.com/
- Ownership
- Privately Held (backing)
VerImmune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VerImmune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VerImmune in its N-PORT filings yet. We sweep new filings monthly.